Trials / Active Not Recruiting
Active Not RecruitingNCT06926803
A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Qiming Wang · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study adopts a retrospective design. Patients enrolled will include those who received furmonertinib (treatment duration ≥1 month) between March 3, 2021, and December 31, 2024, with concurrent therapies permitted (e.g., radiotherapy, intrathecal chemotherapy, surgical interventions such as ventriculoperitoneal shunting). A retrospective analysis will be conducted to investigate the efficacy and safety of furmonertinib-based therapy (with or without other treatments) in EGFR-mutated NSCLC patients with leptomeningeal metastasis.
Conditions
Timeline
- Start date
- 2025-03-01
- Primary completion
- 2025-06-30
- Completion
- 2025-08-01
- First posted
- 2025-04-15
- Last updated
- 2025-04-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06926803. Inclusion in this directory is not an endorsement.